Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

证券日报网讯华神科技（000790）9月22日在互动平台回答投资者提问时表示，目前山东凌凯项目仍在 一期项目建设中，一期项目投资尚未全部完成。上海凌凯持有的山东凌凯股权公司暂无收购计划，后续 若有上述计划，公司将根据该事项的进展情况依据相关法律法规的规定和要求履行相应的程序并披露， 敬请关注公司公告。 ...

Group 1 - The company is currently focused on the first phase of the Shandong Lingkai project, which is still under construction and has not yet completed all investments for this phase [2] - There are no current plans for the company to acquire shares held by Shanghai Lingkai Technology in the Shandong Lingkai project [2] - The company will disclose any future plans regarding acquisitions based on the progress of the matter and in accordance with relevant laws and regulations [2]

Group 1 - The company, Huasheng Technology, announced that as of now, it and its controlling subsidiaries do not provide guarantees to entities outside the consolidated financial statements [2] - There are no overdue debts corresponding to guarantees, nor are there any guarantees related to litigation or losses due to adverse judgments [2]

证券代码：000790 证券简称：华神科技 公告编号：2025-041 成都华神科技集团股份有限公司 上述授信和担保额度在公司 2025 年度授信和担保额度预计范围内，该事项无需提交公 司董事会或股东大会审议。 三、被担保人基本情况 （一）公司名称：成都华神科技集团股份有限公司 1、注册地址：成都高新区（西区）蜀新大道1168号2栋1楼101号 2、设立时间：1988年1月27日 3、注册资本：623,719,364元人民币 关于提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 成都华神科技集团股份有限公司（以下简称"公司"或"华神科技"）于 2025 年 4 月 27 日、2025 年 5 月 22 日分别召开了第十三届董事会第二十次会议、2024 年年度股东大会， 审议通过了《关于 2025 年度公司及子公司向金融机构申请综合授信及担保额度预计的议 案》，同意 2025 年度公司（含子公司）拟申请银行及非银行金融机构综合授信 10.60 亿元 人民币，2025 年度预计新增公司及子公司相互提供担保额度（包括公司为子公司提 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、成都华神科技集团股份有限公司（以下简称"公司"）通过西南联合产权交易所以公开挂牌方式转让 公司控股子公司西藏康域药业有限公司（以下简称"西藏康域"）51%股权（以下简称"本次交易"）。经 西南联合产权交易所审核及公司确认，确定李正洪为合格受让方，转让价格为4,250万元。 2、本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 3、交易完成后，公司将不再持有西藏康域股权，西藏康域不再纳入公司合并报表范围。 一、交易概述 为了进一步集中资源聚焦优势业务，提升公司盈利能力和核心竞争力，推动公司高质量发展，公司于 2025年8月1日召开了第十三届董事会第二十三次会议、2025年8月19日召开了2025年第一次临时股东大 会，审议通过了《关于公司拟公开挂牌转让西藏康域51%股权的议案》，同意公司公开挂牌转让控股子 公司西藏康域51%股权，并以评估值6,378.06万元作为首次挂牌底价。具体内容详见公司于2025年8月2 ...

Group 1: Product Development and Market Focus - LiFSI is used as an additive in lithium-ion battery electrolytes, enhancing conductivity and thermal stability; currently in technical modification and customer trial phases [2] - The company is focusing on the core business of the Sanqi industry chain and ecosystem, considering both internal investment and external mergers and acquisitions to enhance resource integration [3] - The Shandong Lingkai project is in the technical modification and customer trial stage, with no revenue generated yet [4] Group 2: Financial Performance and Strategic Adjustments - The company has experienced significant performance declines and losses due to price reductions after core product bidding, adjustments in customer procurement strategies, and a strategic contraction of the steel structure business [4] - The company is actively divesting non-core business investments, including transferring subsidiaries and shares in Shanghai Lingkai and Tibet Kangyu [4] - The company is evaluating potential acquisitions, such as Sichuan Meifeng, which has a strong balance sheet and a low debt ratio of around 20% [3] Group 3: Innovation and Product Diversification - The company is committed to enhancing the stability and safety of drug efficacy, with successful clinical trials for Sanqi Tongshu capsules in treating ischemic stroke [4] - The company aims to strengthen its market position in the bottled water sector, holding the top market share in Chengdu and second in Sichuan [4] - The company is exploring new product development and strategic partnerships to diversify its product offerings [4] Group 4: Investor Relations and Future Outlook - The company assures that it is not at risk of delisting and is operating normally [4] - The management emphasizes that recent divestitures were strategic decisions aimed at consolidating resources to enhance core competitiveness and long-term profitability [4] - The company is continuously monitoring market opportunities and will make investment decisions based on strategic alignment and risk assessment [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、成都华神科技集团股份有限公司（以下简称"公司"）通过西南联合产权交易所以公 开挂牌方式转让公司控股子公司西藏康域药业有限公司（以下简称"西藏康域"）51%股权 （以下简称"本次交易"）。经西南联合产权交易所审核及公司确认，确定李正洪为合格受 让方，转让价格为 4,250 万元。 成都华神科技集团股份有限公司 关于公开挂牌转让控股子公司 51%股权的进展公告 证券代码：000790 证券简称：华神科技 公告编号：2025-040 2、本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。 2025 年 8 月 21 日公司在西南联合产权交易所首次公开挂牌转让西藏康域 51%股权， 首次挂牌公示期满未能征集到符合条件的意向受让方。 2025 年 8 月 29 日，公司在西南联合产权交易所重新公开挂牌转让西藏康域 51%股权， 挂牌底价为 5,200 万元，本次挂牌公示期满，仍未征集到符合条件的意向受让方。 2025 年 9 月 5 日，公司在西南联合产权交易所重新公开 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-039 本 次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 路 演 " （https://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 12 日（周五） 14:00—17:00。届时公司董事、高管将在线就公司业绩、公司治理、发展战略、 经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 成都华神科技集团股份有限公司 董 事 会 二〇二五年九月九日 成都华神科技集团股份有限公司 关于参加四川辖区 2025 年投资者网上集体接待日 及半年度报告业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，成都华神科技集团股份有限公司（以下 简称"公司"）将参加由四川省上市公司协会、深圳市全景网络有限公司联合举 办的"四川辖区 2025 年投资者网上集体接待日及半年度报告业绩说明会"活动， 现将相关事项公告如下： ...

Core Viewpoint - Huasheng Technology plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., for 42.5 million yuan, following a previous acquisition at 51 million yuan, indicating a strategic shift amid performance issues and regulatory scrutiny [1][4][6]. Group 1: Equity Transfer Details - The initial acquisition of 51% equity in Tibet Kangyu was completed for 51 million yuan in August 2023, with performance guarantees for net profits of 15 million yuan, 20 million yuan, and 25 million yuan for the years 2023 to 2025 [4]. - The transfer price has decreased from 63.78 million yuan to 42.5 million yuan over three attempts to sell the equity, reflecting a significant drop in perceived value [3][4]. - The first two attempts to transfer the equity in August 2023 did not attract any interested buyers, leading to a third attempt [3]. Group 2: Performance and Compliance Issues - In 2023, Tibet Kangyu met its performance commitments, but in 2024, it only achieved a net profit of approximately 16.78 million yuan, representing an 83.92% completion rate of the commitment [4]. - The company faced allegations of improper revenue recognition and internal control deficiencies, including recognizing revenue without actual product transfer and issues with expense reimbursements [5][6]. - In the first half of 2024, Tibet Kangyu reported a net profit of 458.43 million yuan, fulfilling only 18.34% of its annual profit commitment [5]. Group 3: Huasheng Technology's Financial Performance - Huasheng Technology experienced a significant decline in performance, with a reported revenue of 864 million yuan in 2024, down 13.89% year-on-year, and a net loss of 6.69 million yuan [6]. - In the first half of 2025, the company reported a revenue of 292 million yuan, a 36.29% decrease year-on-year, and a net loss of 54.84 million yuan, marking a 702.09% decline [6]. - The decline in performance is attributed to increased costs in its main product and a strategic reduction in its construction steel structure business [6].